Critical Contrast: Celsion (NASDAQ:CLSN) Vs. Supernus Pharmaceuticals (NASDAQ:SUPN)
Critical Contrast: Celsion (NASDAQ:CLSN) Vs. Supernus Pharmaceuticals (NASDAQ:SUPN)
Celsion (NASDAQ:CLSN – Get Rating) and Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.
凱爾特(納斯達克：CLSN-GET評級)和Supernus PharmPharmticals(納斯達克：SUPN-GET評級)都是小盤醫療公司，但哪一家是優勢投資？我們將根據分析師推薦的風險、估值、收益、盈利能力、機構所有權和股息對這兩家公司進行對比。
Volatility & Risk
波動性與風險
Celsion has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
Celsion的貝塔係數為2.27，這意味着其股價的波動性比標準普爾500指數高127%。相比之下，Supernus PharmPharmticals的貝塔係數為1.01，這意味着其股價的波動性比標準普爾500指數高1%。
Profitability
盈利能力
This table compares Celsion and Supernus Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了Celsion和Supernus製藥公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Celsion | -5,229.80% | -50.18% | -36.94% |
| Supernus Pharmaceuticals | 9.12% | 6.98% | 3.50% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 凱爾遜 | -5,229.80% | -50.18% | -36.94% |
| Supernus製藥公司 | 9.12% | 6.98% | 3.50% |
Analyst Recommendations
分析師建議
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celsion | 0 | 0 | 1 | 0 | 3.00 |
| Supernus Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 凱爾遜 | 0 | 0 | 1 | 0 | 3.00 |
| Supernus製藥公司 | 0 | 0 | 2 | 0 | 3.00 |
Celsion currently has a consensus target price of $16.00, indicating a potential upside of 672.95%. Supernus Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 18.39%. Given Celsion's higher possible upside, analysts plainly believe Celsion is more favorable than Supernus Pharmaceuticals.
Celsion目前的共識目標價為16.00美元，表明潛在上行672.95%。Supernus PharmPharmticals的共識目標價為41.00美元，表明潛在上漲18.39%。鑑於Celsion的上行可能性更高，分析師顯然認為Celsion比Supernus PharmPharmticals更有利。
Earnings and Valuation
收益和估值
This table compares Celsion and Supernus Pharmaceuticals' top-line revenue, earnings per share and valuation.
該表格比較了Celsion和Supernus PharmPharmticals的營收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celsion | $500,000.00 | 29.39 | -$20.77 million | N/A | N/A |
| Supernus Pharmaceuticals | $579.78 million | 3.20 | $53.42 million | $1.01 | 34.29 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 凱爾遜 | $500,000.00 | 29.39 | -2,077萬元 | 不適用 | 不適用 |
| Supernus製藥公司 | 5.7978億美元 | 3.20 | 5,342萬美元 | $1.01 | 34.29 |
Supernus Pharmaceuticals has higher revenue and earnings than Celsion.
Supernus PharmPharmticals的收入和收益高於Celsion。
Institutional and Insider Ownership
機構和內部人持股
13.0% of Celsion shares are held by institutional investors. Comparatively, 99.8% of Supernus Pharmaceuticals shares are held by institutional investors. 4.7% of Celsion shares are held by insiders. Comparatively, 8.7% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Celsion 13.0%的股份由機構投資者持有。相比之下，Supernus PharmPharmticals 99.8%的股份由機構投資者持有。Celsion 4.7%的股份由內部人士持有。相比之下，Supernus PharmPharmticals 8.7%的股份由內部人士持有。強大的機構持股表明，捐贈基金、大型基金管理公司和對衝基金相信，一隻股票有望實現長期增長。
Summary
摘要
Supernus Pharmaceuticals beats Celsion on 8 of the 11 factors compared between the two stocks.
Supernus PharmPharmticals在兩隻股票比較的11個因素中有8個擊敗了Celsion。
About Celsion
關於Celsion
(Get Rating)
(獲取評級)
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Celsion公司是一家臨牀階段生物技術公司，專注於基於DNA的免疫療法、疫苗和定向化療的開發和商業化。它的產品線包括GEN-1，一種用於卵巢癌局部治療的基於DNA的免疫療法；以及ThermoDox，一種阿黴素的專有熱激活脂質體膠囊，正處於各種癌症適應症的開發階段。該公司還擁有兩項可行性階段平臺技術，用於開發基於核酸的免疫療法、疫苗和其他抗癌DNA或RNA療法。Celsion Corporation成立於1982年，總部設在新澤西州的勞倫斯維爾。
About Supernus Pharmaceuticals
關於Supernus製藥公司
(Get Rating)
(獲取評級)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Supernus製藥公司是一家生物製藥公司，在美國專注於治療中樞神經系統(CNS)疾病的產品的開發和商業化。它的商業產品是Trokendi XR，這是一種用於治療癲癇和預防偏頭痛的託吡酯緩釋劑；奧克泰拉XR是一種緩釋型奧卡西平，用於單一療法治療6至17歲的成人和兒童部分發作癲癇。該公司的商業產品還包括用於治療6至17歲兒童注意缺陷多動障礙(ADHD)患者的選擇性去甲腎上腺素再攝取抑制劑Qelbree；用於治療晚期帕金森病(PD)患者運動能力低下或發作間歇的Apokyn；用於治療帕金森病非發作患者的左旋多巴/卡比多巴的XADAGO；用於治療成人頸部肌張力障礙和流涎的B型毒素產品Myobloc；用於治療PD患者的運動障礙的GOCOVRI；以及用於治療成人帕金森病和藥物引起的錐體外系反應的Osmolex ER。此外，它的候選產品還包括用於治療多動症的第三階段臨牀試驗已經完成的Qelbree(SPN-812)；用於防止帕金森病患者發作的晚期候選藥物/設備組合產品SPN-830；用於治療嚴重癲癇的第一階段臨牀試驗的候選新產品SPN-817；用於治療難治性抑鬱症的第二階段臨牀試驗候選產品SPN-820；以及處於治療中樞神經系統疾病的臨牀前階段的SPN-443和SPN-446。該公司通過藥品批發商、專業藥店營銷和銷售其產品。, 和分銷商。該公司成立於2005年，總部設在馬裏蘭州的羅克維爾。
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.
接受《凱爾遜日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Celsion和相關公司的最新新聞和分析師評級的每日簡要摘要。